期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多靶点酪氨酸激酶抑制剂帕纳替尼的研究进展 被引量：2

Research Progress of Multi-targeted Tyrosine Kinase Inhibitor-Ponatinib
暂未订购
导出
摘要 帕纳替尼是美国FDA在2012年批准的多靶点酪氨酸激酶抑制剂,能够有效抑制BCR-ABLT315I突变的TKI,该药物毒性通常较低.帕纳替尼是新药研制过程中的大突破,是一种对白血病疗效较好,毒副作用较低的多靶点酪氨酸激酶抑制剂. Ponatibib is a multi-targeted tyrosine kinase inhibitor approved by the FDA in 2012,it can effectively inhibit BCR-ABLT315 Imutation TKI and the toxicity of the drug is usually lower.Ponatibib has better effect on Leukemia and lower side effects on body. It is a breakthrough in the development of newdrugs.
作者 刘举 张美荣 王洋 周云鹏 陈烨
机构地区 辽宁大学药学院
出处 《辽宁大学学报（自然科学版）》 CAS 2014年第4期347-355,共9页 Journal of Liaoning University：Natural Sciences Edition
关键词 多靶点酪氨酸激酶 白血病 药理作用 临床应用 合成路线 multi-targeted tyrosine kinase leukemia pharmacological effects clinical application synthetic route
分类号 R963 [医药卫生—微生物与生化药学]
  • 相关文献

参考文献2

二级参考文献19

  • 1[1]Ciardiello F,Caputo R,Bianco R,et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clin Cancer Res,2001,7:1459
  • 2[2]Bruns C J,Solorzano CC,Harbison MT,et al.Blockade of the epidermal growth factor receptor signaling by a novel tyrosine ki nase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.Cancer Res,2000,60:2926
  • 3[3]Wedge SR,Ogilvie DJ,Dukes M,et al.ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis,and tumor growth following oral administration.Cancer Res,2002,62:4645
  • 4[4]Wedge SR,Ogilvie,Dukes M,et al.Pharmacological efficacy of ZD6474,aVEGF receptor tyrosine kinase inhibitor,in rat. (Abstract) Proceedings of the 92nd Annal Meeting of the Ameri cian Association for Cancer Research,New Orleans (LA), 2001,42:Abst3126,583
  • 5[5]Wedge SR,Checkley D,Tessier JJ,et al.Dynamic contrast -enhanced MRI study of human xenografts treated with the VEGF signaling inhibitor ZD6474.Proceedings of the 92nd Annu al Meeting of the American Association for Cancer Research, New Orleans (LS),2001,42:Abst 581,107
  • 6[6]Manie S,Santoro M,Fusco A,et al.The RET receptor: Function in development and dysfunction in congenital malforma tion.Trends Genet,2001,17:580
  • 7[7]Carlomagno F,Vitagliano D,Guida T,et al.ZD6474,an orally available inhibitor of KDR tyrosine kinase activity,effi ciently blocks oncogenic RET kinases.Cancer Res,2002,62: 7284
  • 8[8]Ciardiello F,Caputo R,Damiano V,et al.Antitumor effects of ZD6474,a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor,with additional activity against epidermal growth factor receptor tyrosine kinase.Clin Cancer Res,2003,9:1546
  • 9[9]Bruns C J,Kohl G,Guba M,et al.Anti-angiogenic and anti -tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.Proc Am Assoc Cancer Res (2nd ed),2003,44:604
  • 10[10]Williams KJ,Telfer BA,Brave S,et al.ZD6474,a potent inhibitor of vascular endothelial growth factor signaling,com bined with radiotherapy:Schedule-dependent enhancement of antitumor activity.Clin Cancer Res,2004,10:8587

共引文献19

同被引文献25

  • 1Costa R M G D. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell [J]. Vet J, 2015, 205(1) : 5-10.
  • 2Letard S, Yang Y, Hanssens K, et al. Gain-of-function muta- tions in the extracellular domain of KIT are common in canine mast cell tumors[J]. Mol Cancer Re,2008, 6(7) : 1137-1145.
  • 3Gilfillan A M, Rivera J. The tyrosine kinase network regula- ting mast cell activation[J]. Immunol Rev, 2009, 228 (1) : 149-169.
  • 4Roskoski R. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor[J]. Biochem Biophy Res Co,2005, 338(3): 1307-1315.
  • 5Takeuchi Y, Fujino Y, Watanabe M, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumors: A retrospective cohort study[J]. Vet J,2013, 196(3) : 492-498.
  • 6Bonkobara M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice[J]. Vet J, 2015, 205 (2) : 180-188.
  • 7Withrow S J M. Small Animal Clinical Oncology[M]. Sanud- ers:2012: 330-346.
  • 8Blackwood L, Murphy S, Buracco P, et al. European consen- sus document on mast cell tumors in dogs and eats[J]. Vet Comp Oncol,2012: 10(3): e1-e29.
  • 9London C A. Tyrosine kinase inhibitors in veterinary medi- cine[J]. Topics Compa Anim Med, 2009, 24(3): 106-112.
  • 10Eisenhauer E A, Therasse P, Bogaerts J, et al. New re- sponse evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009, 45(2) : 228- 247.

引证文献2

二级引证文献9

辽宁大学学报（自然科学版）
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部